Jeremy Cooper
preprint
Presentations of existential anxiety within depersonalization-derealization disorder both present as symptoms to be reduced and highlight a particular trend for understanding self-referential processes. In offering a possible neurophenomenological conceptualization of how oneself attempts to understand oneself through the course of experiencing existential anxiety, a lens through Spinoza’s...
Jason B. Luoma, M. Kati Lear, Kyong Yi et al.
preprint
This case report describes the application of in vivo and imaginal exposure techniqueswithin MDMA-assisted therapy (MDMA-AT) for social anxiety disorder (SAD). The treatment,conducted as part of a randomized controlled trial, consisted of three non-drug preparationsessions, two drug sessions, and six non-drug integration sessions. Exposure interventionsincluded imaginal exposure to...
Acacia C Parks, Amanda L Woodward, Robert D Henry et al.
BACKGROUND Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and Post-Traumatic Stress Disorder (PTSD) are leading global causes of disability. Standard interventions often suffer from slow mechanisms of action, high attrition, and significant accessibility barriers. While intravenous (IV) and intranasal ketamine have emerged as rapid-acting alternatives, their high cost and...
Psychopharmacology
October 26, 2026
Aline Frick, Grace Blest‐hopley, Manesh Girn et al.
Major depressive disorder (MDD) shows marked sex differences in prevalence, symptomatology, and treatment response. However, females remain underrepresented in many clinical trials, and sex-specific treatment outcomes are rarely examined. This study reanalyzed data from a randomized controlled trial comparing psilocybin and escitalopram for MDD to evaluate sex differences across multiple...
Psychopharmacology
October 17, 2026
Sixtine Fleury, Yian Shang, Katherine M. Nautiyal
Psilocybin can produce rapid and sustained antidepressant-like and anxiolytic effects, yet the receptor and circuit mechanisms underlying these behavioral changes remain unclear. While the serotonin 2A receptor mediates psilocybin's acute psychedelic effects, psilocin (the active metabolite of psilocybin) binds many serotonin receptor subtypes. Our prior work has identified the serotonin 1B...
Journal of Neural Transmission
September 19, 2026
Guilherme Lodetti, Henrique Redivo, Amanda Gomes Teixeira et al.
Pharmacotherapy for depression is commonly prescribed, yet fewer than half of patients achieve remission with a single treatment. Many also experience intolerable side effects, highlighting the need for new treatment approaches. Classic psychedelics interact with the serotonin (5-HT) receptor class and are therefore strongly involved in the treatment of psychiatric illnesses such as depression,...
Neuropsychological rehabilitation
September 7, 2026
Purani Bogahawatta, Ashan Wijekoon, Thameesha Harini et al.
Scientific interest in mindfulness meditation as complementary therapy for Parkinson's disease (PD) has grown significantly. This systematic review examined mindfulness meditation effects on PD motor, cognitive, falls-related (fear of falling (FoF), freezing of gait (FoG), falls prevention), psychological (anxiety and depression), physical (balance, mobility, gait velocity), and quality of life...
Journal of Medical Internet Research
September 2, 2026
Kathrin Hassdenteufel, Mitho Müller, Jan Multmeier et al.
Background: Pregnant women with ICD-10 (International Statistical Classification of Diseases, Tenth Revision) affective or stress-related disorders face an elevated risk of perinatal depression and anxiety, yet evidence on digital nonpharmacologic interventions for this population remains limited. Objective: This study evaluated the effectiveness of an 8-week digital mindfulness-based...
Psycho-Oncology
September 1, 2026
Shu Jing, Zhenwei Dai, Xuelin Yang et al.
Background: Patients with cervical cancer or High-Grade Squamous Intraepithelial Lesion (HSIL) often experience mental problems such as anxiety and depression. Online mindfulness-based interventions offer accessible mental health support. However, evidence for cervical cancer or HSIL patients remains scarce, and evaluations often rely solely on self-reported scales, with a lack of...
Clinical Therapeutics
September 2026
Jonathon K. Lisano, Luiza Rosa, Greg Giordano et al.
Emerging research indicates that the use of cannabis products, particularly those higher in cannabidiol (CBD), may be anxiolytic. Physical activity is another modality observed to have anxiolytic effects. Despite evidence of cannabis and physical activity being paired together, there is limited research on the possible synergistic effects of physical activity and cannabis use on reductions in...